India scaling up production of APIs: NITI Aayog CEO Amitabh Kant

India, a global hub for generic drugs, has launched a new scheme to boost production of active pharmaceutical ingredients (APIs) that are greatly dependent on the Chinese supply chain, according to NITI Aayog CEO Amitabh Kant.

migrator

Updated:9th Sep, 2020 at 1:58 AM

New Delhi

Speaking at the 14th Annual BioPharma and Healthcare Summit, he said India is now gearing up for innovation in its pharmaceutical ecosystem focusing on speedy and scaled up delivery of new vaccines and personalised medicines.

He said India has launched a new scheme to boost production of active pharmaceutical ingredients that are greatly dependent on the Chinese supply chain. “We are planning to do complete manufacturing in India,” he said at the recently-held virtual summit organised by the USA-India Chamber of Commerce.

The summit was attended by major players from the US pharma sector, whose combined annual R&D budget is over $45 billion.

India scaling up production of APIs: NITI Aayog CEO Amitabh Kant

India, a global hub for generic drugs, has launched a new scheme to boost production of active pharmaceutical ingredients (APIs) that are greatly dependent on the Chinese supply chain, according to NITI Aayog CEO Amitabh Kant.

Also Read

CM Vijay inaugurates Rs 23 crore bus stand in Pudukottai

TASMAC retail outlets remain State-run as govt revises rules for private bars

Perambalur: Former panchayat chief hacks to death collegeboy for being in touch with his minor daughter

Tamil Nadu examining possibility of privatising liquor sales, says Minister K Vignesh

Madurai rowdy hacked to death near Samayanallur